Statens Serum Institut
København Doing business as Statens Serum Institut
- UEI
- K4FZERGGGF51
- CAGE
- R4081
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Country - Foreign Government
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- Artillerivej 5, 2300 København, Denmark
- Website
- ssi.dk
- Founded
- 1902
- Employees
- 1K-5K
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Financials
- Diversified Financials
- Capital Markets
- Diversified Capital Markets
- SIC code
- 67 Holding & Other Investment Offices
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Dissecting the role of vaccine-promoted TH17 cells in protective immunity against tuberculosis - abstract an effective… | National Institute of Allergy and Infectious Diseases | $1,379,158 | |
| A dual function TB subunit vaccine designed for non-interference with BCG and post-exposure activity | National Institute of Allergy and Infectious Diseases | $6,447,137 | |
| Acid inhibitor therapies and risk of gastric cancer by anatomic subsite | National Cancer Institute | $15,000 | |
| Purchase Order HHSD2002013M55139P | CDC Office of Acquisition Services | $50,000 | |
| Genome-wide association study of febrile seizures following measles, mumps, rubel | National Institutes of Health | $588,531 |
About Statens Serum Institut
Statens Serum Institut is a Danish government-owned infectious disease research and public health organization registered in the U.S. federal government's System for Award Management (SAM) since 2002, with its current registration valid until January 28, 2026. As a foreign government entity, the organization provides specialized research and vaccine development services to U.S. federal agencies, focusing primarily on infectious disease studies, vaccine research, and immunological investigations. Its work spans multiple critical areas of medical research, with a particular emphasis on developing innovative approaches to understanding and combating infectious diseases.
Through federal contract sub-awards, Statens Serum Institut has been involved in sophisticated vaccine and immunology research projects. Key contract work includes collaborative efforts with Seattle Children's Hospital examining innate and adaptive immunity from vaccination, specifically addressing nontuberculous mycobacteria (NTM) interference, RNA delivery, and vaccine design strategies for Mycobacterium tuberculosis. Additionally, the organization has participated in malaria vaccine development projects with Path, supporting innovative approaches to vaccine research that encompass preclinical development and clinical study design. These contract activities demonstrate the organization's expertise in advanced immunological research, vaccine optimization, and cross-species immunogenicity assessments.
On the federal grant side, Statens Serum Institut has received significant awards, most notably a $666,567 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) focused on tuberculosis vaccine research. This grant, awarded in August 2025, aims to investigate the role of vaccine-induced Th17 cells in protective immunity against tuberculosis, with research objectives including assessing early neutrophil recruitment and identifying biomarkers related to Th17 cell responses. The organization has also been involved in sub-grant awards related to global vaccine safety monitoring, sexually transmitted infection research, and epidemiological studies. These grant activities highlight Statens Serum Institut's broad capabilities in infectious disease research, immunology, vaccine development, and epidemiological investigations across multiple critical health domains.
Quick answers
What is Statens Serum Institut's UEI?
Statens Serum Institut's Unique Entity ID (UEI) in SAM.gov is K4FZERGGGF51.
What is Statens Serum Institut's CAGE code?
Statens Serum Institut's CAGE code is R4081.
What is Statens Serum Institut's primary NAICS code?
Statens Serum Institut's primary NAICS code is 541715 (Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)).
Where is Statens Serum Institut located?
Statens Serum Institut's physical address in SAM.gov is Artillerivej 5, 2300 København, Denmark.
Is Statens Serum Institut registered in SAM.gov?
Yes. Statens Serum Institut's SAM.gov registration is active through December 19, 2026.
What is Statens Serum Institut's most recent federal award?
Statens Serum Institut's most recent federal grant award is Dissecting the role of vaccine-promoted TH17 cells in protective immunity against tuberculosis - abstract an effective… (R01AI185516), from National Institute of Allergy and Infectious Diseases, on August 19, 2025.
On GovTribe
See Statens Serum Institut's full federal record
- Federal contract awards
- Federal grant awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors